Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association
Medicina | Free Full-Text | Clinical Manifestations of Kawasaki Disease at Different Age Spectrum: A Ten-Year Study
Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997–2010: Effect of different case definitions in claims data analysis - ScienceDirect
Frontiers | Epidemiology of Kawasaki Disease in Europe
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
Is it Kawasaki Disease or Multisystem Inflammatory Syndrome in Children? - ScienceDirect
Kawasaki's Disease - Don't Forget the Bubbles
Kawasaki Disease: Practice Essentials, Background, Pathophysiology
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Kawasaki Disease: Practice Essentials, Background, Pathophysiology
Recurrent Kawasaki disease presenting as acute airway obstruction
Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up | Archives of Disease in Childhood
Recurrent Kawasaki disease and cardiac complications: nationwide surveys in Japan | Archives of Disease in Childhood
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution | PLOS ONE
Kawasaki disease in children: Epidemiology, clinical symptoms and diagnostics of 231 cases in 10 years
Clinical Practice Guidelines : Kawasaki disease
Combination therapy reduces risk for abnormalities, treatment failure in Kawasaki disease
Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study | PLOS ONE
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease | Circulation
Kawasaki Disease
Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
Children | Free Full-Text | Major Complication Following Kawasaki Disease in an Infant—The Development of Apical Infarction and Aneurysm Formation
The up‐to‐date pathophysiology of Kawasaki disease - Hara - 2021 - Clinical & Translational Immunology - Wiley Online Library
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Abstract 134: Early Immunoglogulin Therapy and Outcomes of Kawasaki Disease | Circulation
